The ALS Association, LAS Finding a Cure and Massachusetts General Hospital recently invested approximately $3.6 million to broaden the NeuroBANK program, which offers core and infrastructure services to ALS research communities.
The goal of the expansion is to benefit the international ALS research community as well as patient-centric clinical research, which must be sped up in order to help more patients around the world.
New funds will continue to help the ongoing studies, research and successes of the program. Gaining more common data elements as well as developing operating procedures will help people around the world.
“We are immensely grateful for the generous support from our visionary sponsors,” Alexander Sherman, creator of NeuroBANK, said. “Implementation of this project will advance ways to categorize people with ALS, develop new disease staging models, identify new pathways for treatment and introduce a crucial foundation for new clinical trials.”
The financing is part of the ALS Accelerated Therapeutics (ALS-ACT) initiative. The organizations first established this initiative in 2014.
“We are very pleased to be able to support expansion of the NeuroBANK program,” Dr. Lucie Bruijn, chief scientist for The ALS Association, said. “The establishment of these cross-study resources has been a boon to research, and we anticipate that the growth of the program made possible by this new round of funding will greatly increase its value to the ALS research community. This has been a pivotal step to collaboration, data access and centralization of all the research activities engaging people living with ALS.”
